# A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

> **NCT04260256** · PHASE2 · TERMINATED · sponsor: **CellSight Technologies, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit

## Interventions

- **DRUG:** [18F]F-AraG

## Key facts

- **NCT ID:** NCT04260256
- **Lead sponsor:** CellSight Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-01
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** lack of funding
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04260256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04260256, "A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04260256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*